パートナー
主に化学、製薬分野の特許訴訟、控訴を中心業務とする。米国連邦地方裁判所のあらゆる法廷で審理事件を扱い、仲裁及び調停手続きも手掛ける。公判、マークマン・ヒアリング、及び控訴審では主任弁護士として訴訟チームを牽引する。
幅広い訴訟経験には、公判での証人尋問、終局的判断を求める申立書の作成及び弁護、控訴趣意書の作成、控訴審での弁護を含む。また、複数の当事者が関与する係争事件の訴訟アクティビティを日々管理する。さらに、権利化手続のコーディネート、米国及び海外で発生した訴訟への戦略構築、等様々な特許問題で助言する。
Patent Resources Group Inc.化学特許実務コースの講師。シカゴ大学で修士号及び博士号を取得する際、レーザーシステムの設計及び小分子の分光分析を実施した。
業務の一環として積極的にプロボノ活動に携わり、現在、弊所プロボノ委員会の委員長を務める。軍関係者の代理人として、戦闘中の負傷等、兵役中に被った負傷に対する損害賠償の増額を求める弁護を担う。また、合衆国退役軍人請求控訴裁判所、連邦巡回控訴裁判所で退役軍人の代理人も務める。
Biogen International GmbH v. Teva Pharmaceuticals USA, Inc.
1:17-cv-00829, D. Del., Judge Noreika
1:17-cv-00116, N.D.W. Va., Judge Keeley
Vifor (International) AG and American Regent, Inc. v. Mylan Labs. Ltd. et al.
3:19-cv-13955, 3:19-cv-16305, D.N.J., Judges Wolfson, Arpert
Ferring B.V. v. Allergan, Inc.
Represented Ferring in inventorship litigation, relating to desmopressin pharmaceutical compositions, acting as co-lead counsel at trial.
1:12-cv-02650, S.D.N.Y., Judges Cott, Sweet
Otsuka Pharmaceutical Co., Ltd. v. Apotex Corp.
Represented Otsuka in 24 related Hatch-Waxman litigations concerning Otsuka’s Ability® tablet products and acted as lead counsel on appeal.
1:14-cv-01078, -04671, -02982, -07405, -05878, -06398 -08074 -03306, -06890, -05876, -08077, -03168, -07252, -07105 -05537, -03996, -06158, -04508, -04307, -06397, -07106, -01979, -03445; 1:15-cv-0161, -07584, -01585, -07803, -08830, -05109, -07802, -08955, -01716, -01967, -06353, -08305; 1:16-cv-05288, -05400, -05949, -07705 -02475, -02476, -08284, -05743, -00086, -08085, -00555, -00557, -07346, -06067, -00405, -00424, -05688, -09603; 1:17-cv-02754, -00392, D.N.J., Judges Simandle, Williams
Prosecuting patents for startup Hutchison Medipharma
Finnegan prepared and prosecuted patents for startup Hutchison Medipharma in the United States for the treatment of metastatic colorectal cancer. Those patents cover a small molecule, fruquintinib, which received approval in China.
Finnegan tees up valuable patents for Principia Biopharma, leading to major acquisition deal
Completed successful patent prosecution for Principia. By entrusting Finnegan to obtain strong patents for their Phase 1 candidate, Principia was able to secure an exclusive, worldwide license agreement with Sanofi to develop and commercialize PRN2246, with the potential for $765 million in milestone payments. Finnegan also successfully prosecuted patents directed to compound PRN1008, a BTK inhibitor that Principia is investigating for autoimmune and inflammatory diseases. Principia’s impressive pipeline of drug candidates, covered by a patent portfolio prosecuted by Finnegan, led to an IPO in which Principia raised over $100 million.
Event
Carolina Patent, Trademark & Copyright Law Association Fall CLE Carolina Patent, Trademark & Copyright Law Association Fall CLE
September 29-30, 2023
Kiawah Island
Event
Proving and Avoiding Inequitable Conduct and Unclean Hands in Patent Prosecution and Litigation Proving and Avoiding Inequitable Conduct and Unclean Hands in Patent Prosecution and Litigation
August 17, 2023
Webinar
Prosecution First Blog
ChromaDex Fails to Milk Its Patent for Subject Matter Eligibility ChromaDex Fails to Milk Its Patent for Subject Matter Eligibility
March 17, 2023
Prosecution First Blog
Inequitable Conduct Claim Can Progress Even After the Case Is Complete Inequitable Conduct Claim Can Progress Even After the Case Is Complete
December 9, 2022
At the PTAB Blog
Inequitable Conduct Claim Can Proceed Even After the Case Is Over Inequitable Conduct Claim Can Proceed Even After the Case Is Over
December 7, 2022
Event
2022 All Ohio Annual Institute on Intellectual Property 2022 All Ohio Annual Institute on Intellectual Property
October 11-12, 2022
Virtual
Award/Ranking
Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars Finnegan Receives Tier 1 Benchmark Litigation Rankings; Nine Attorneys Named Litigation Stars
October 5, 2023
Benchmark LitigationAward/Ranking
54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll 54 Finnegan Attorneys Named to 2022 Capital Pro Bono Honor Roll
July 21, 2023
Press Release
Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board Managing Intellectual Property IP Stars: Finnegan Scores Top Patent Rankings Across the Board
July 13, 2023
Managing Intellectual PropertyCommentary
Are Winds of Change Finally Blowing on Patent Eligibility? Are Winds of Change Finally Blowing on Patent Eligibility?
December 21, 2022
Law360Announcement
Finnegan Earns Tier 1 Benchmark Litigation Rankings for Intellectual Property Work, with Five Partners Recognized as Litigation Stars Finnegan Earns Tier 1 Benchmark Litigation Rankings for Intellectual Property Work, with Five Partners Recognized as Litigation Stars
October 3, 2022
Benchmark LitigationDue to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.